LOS ANGELES, Sept. 26, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the Livingston Securities 7th Annual Life Sciences Stakeholders Summit at 1:55 pm ET on Wednesday, October 1, 2014, at the Cira Center in Philadelphia, PA.
To access the live audio webcast of the Livingston Securities presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. The event can also be accessed at: https://www1.gotomeeting.com/join/656225217; (571) 317-3112, Access Code 656-225-217. The audio PIN will be shown after joining the meeting using meeting ID 656-225-217. A replay of the presentation will be available.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells and a preclinical antigen-specific T-cell therapy program. To learn more about ImmunoCellular, please visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
SOURCE ImmunoCellular Therapeutics, Ltd.
